Key facts
- Ten63 Therapeutics’s last known valuation is $979.0M (Jan 2025).
- It has raised $50.5M across 1 recorded rounds; the latest was Seed Round ($2.1M) in Jan 2021.
- Notable investors include SOSV, Calm Ventures, Draper Associates, K5 Global, IndieBio — 20 tracked in total.
- Ten63 Therapeutics has filed 1 Form D with the SEC, most recently Jan 2021 ($2.1M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Ten63 Therapeutics
Funding rounds
1 roundsAbout Ten63 Therapeutics
Developer of novel antineoplastic therapeutics designed to create remedial medicines to targets previously believed undruggable. The company's therapeutics are created using algorithms to build proprietary scaffold redesign and hopping technology, combining MOA and chemical design to achieve a more durable response, enabling drug researchers to screen trillions of molecules for resistance prediction and antibody redesign.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2018
- Employees
- 29
- Website
- ten63tx.com/
- Ownership
- Privately Held (backing)
Ten63 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ten63 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ten63 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.